Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Melanoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 41 Breast Neoplasms 34 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Neoplasms 11 Fallopian Tube Neoplasms 10 Endometrial Neoplasms 10 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Recurrence 7 Neoplasm Metastasis 5 Carcinoma, Ovarian Epithelial 5 Sarcoma 4 Lung Neoplasms 4 Glioma 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Solid Tumor 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Carcinoma, Non-Small-Cell Lung 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Neuroendocrine Tumors 2

Interventions

Nivolumab 130 Ipilimumab 122 pembrolizumab 110 Cyclophosphamide 72 Interleukin-2 60 aldesleukin 57 Temozolomide 40 Radiosurgery 36 trametinib 34 Vemurafenib 34 Biopsy 32 fludarabine 31 Blood Specimen Collection 31 dabrafenib 30 Radiotherapy 30 fludarabine phosphate 27 sargramostim 26 Bevacizumab 25 Introns 21 Magnetic Resonance Spectroscopy 20 Dacarbazine 20 encorafenib 17 cobimetinib 17 binimetinib 17 Specimen Handling 17 Granulocyte-Macrophage Colony-Stimulating Factor 17 Paclitaxel 16 Cisplatin 16 incomplete Freund's adjuvant 14 montanide ISA 51 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05482074 2024-01-19

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡